Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2008-07-03 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Imugene`s PRRS vaccine for pigs enters further trials 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 4 July 2008 about Imugene's PRRS vaccine for pigs entering further trials. It describes the commencement of a commercial efficacy trial in the USA, details about the disease, the vaccine development, and commercial prospects. There are no financial statements, no regulatory certifications, no voting results, no management or board changes, no earnings data, and no mention of report attachments or filings. The content is a corporate announcement about product development progress and trial initiation, which does not fit into financial reports or regulatory filings categories. It is not a report publication announcement since it does not mention any report being published or attached. The document is best classified as a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2008-07-03 English
Advisor Incentive Options - Appendix 3B 10 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement dated 30 June 2008 regarding the issuance of 3 million incentive options to Southern Cross Equities Limited as corporate advisory incentive options. It includes detailed information about the terms of the options, exercise price, expiry date, and the purpose of the issue. The document also contains an Appendix 3B, which is a standard form used for new issue announcements and applications for quotation of additional securities on the ASX. The content focuses on the issuance of new securities and related regulatory compliance information. There is no financial performance data, management discussion, or earnings information. The document is not a report but an announcement of a capital/financing activity related to share options issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2008-06-30 English
Becoming a substantial holder 2 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a Form 603 Notice of Initial Substantial Holder under the Corporations Act 2001. It details the substantial shareholding interests, voting power, relevant interests, and acquisition considerations of a shareholder in Imugene Limited. This type of filing is a notification of a major shareholding change, specifically the initial substantial holder notice. It is not a financial report, earnings release, or management report. It fits the definition of Major Shareholding Notification (MRQ). The document length and content confirm it is a substantive notification rather than a brief announcement or certification.
2008-06-11 English
Company Secretary Appointment/Resignation 1 page ?K
Board/Management Information Classification · 100% confidence The document is an ASX release dated 29 May 2008 announcing the appointment of a new Company Secretary and the resignation of the previous one. It contains no financial data, no report or presentation, and no regulatory certification. The content is about a change in senior management position. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on management change, confirming this classification with high confidence.
2008-05-28 English
Cocci Vaccine Trial Success 4 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated May 15, 2008, detailing the successful results of a poultry coccidiosis vaccine trial conducted by Imugene and Abic. It provides a summary of the trial design, results, and commercial implications. The content is focused on a specific scientific and commercial update about vaccine development rather than financial results, management changes, or regulatory filings. It is not a full financial report, earnings release, or management discussion. The document is a corporate announcement about a product development milestone, which fits best under the category of a general regulatory announcement or compliance document that does not fit other specific categories. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (9285 characters) and detailed content confirm it is not a brief report publication announcement or a short notice.
2008-05-14 English
Quarterly Activities Update and Appendix 4C 9 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'IMUGENE QUARTERLY UPDATE' and covers the period from 1 January 2008 to 31 March 2008, indicating it is a quarterly report. It contains detailed operational updates on vaccine development, regulatory progress, and laboratory activities. Importantly, it includes a consolidated statement of cash flows for the current quarter and year to date, which is substantive financial data. The length of the document (15,000 characters) and the presence of financial statements confirm it is a full quarterly report rather than a brief announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2008-04-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.